Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2015

View Archived Issues

Natco Pharma develops Bcr-Abl and Abl kinase inhibitors

S-Oxprenolol improves survival in a preclinical model of ALS

TWi Biotechnology reports interim data from phase II AC-201 CR study in gout patients

SymBio starts Japanese portion of phase III trial of rigosertib in MDS

New intermittent schedule of CC-122 mitigates neutropenia in DLBCL patients

NI-0501 shows promise in pilot study in hemophagocytic lymphohistiocytosis

Target inhibition seen with EPZ-5676 in pediatric patients with MLL-r acute leukemia

New DAAO inhibitor shows promise for CNS disorders

Eisai acquires Liaoning Tianyi Biological Pharmaceutical

FDA accepts IND application for tazemetostat in diffuse large B-cell lymphoma

EnGeneIC reports phase I results for V-EDV-Dox in patients with glioblastoma multiforme

Rich Pharmaceuticals receives FDA clearance to conduct phase I/II study of RP-323

Basilea provides update on ceftobiprole and BAL-101553

Primary endpoint not met in Chimerix's phase III SUPPRESS trial of brincidofovir

Pozen provides update in connection with Tribute transaction

Sacituzumab govitecan has antitumor activity in patients with triple-negative breast cancer

Faron Pharmaceuticals starts phase III trial of Traumakine in ARDS

Chiesi patent describes neutrophil elastase inhibitors

SK Chemicals' SKY Cellflu Quadrivalent approved in South Korea

Redx Pharma discloses BTK inhibitors for cancer

Chinese team develops S. aureus golden pigment synthesis inhibitors

PI3Kdelta inhibitors revealed in Merck & Co. patent

Pfizer reports GABA(A) receptor modulators

Max-Planck-Gesellschaft patent details PDE inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...